These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32952698)

  • 1. Valuation of EQ-5D-3l Health States in Slovenia: VAS Based and TTO Based Value Sets.
    Prevolnik Rupel V; Srakar A; Rand K
    Zdr Varst; 2020 Mar; 59(1):8-17. PubMed ID: 32952698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance among Swedish, German, Danish, and UK EQ-5D-3L Value Sets: Analyses of Patient-Reported Outcomes in the Swedish Hip Arthroplasty Register.
    Teni FS; Rolfson O; Berg J; Leidl R; Burström K
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575317
    [No Abstract]   [Full Text] [Related]  

  • 3. In search of a 'pan-European value set'; application for EQ-5D-3L.
    Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
    BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicative modelling of EQ-5D-3L TTO and VAS values.
    Shafie AA; Vasan Thakumar A
    Eur J Health Econ; 2020 Dec; 21(9):1411-1420. PubMed ID: 32892230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases.
    Zrubka Z; Beretzky Z; Hermann Z; Brodszky V; Gulácsi L; Rencz F; Baji P; Golicki D; Prevolnik-Rupel V; Péntek M
    Eur J Health Econ; 2019 Jun; 20(Suppl 1):119-132. PubMed ID: 31104218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar responses to EQ-5D-3L by two elicitation methods: visual analogue scale and time trade-off.
    Wang X; Zhuo L; Ma Y; Cai T; Must A; Xu L; Zhuo L
    BMC Med Res Methodol; 2020 May; 20(1):118. PubMed ID: 32410582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Niewada M; Wrona W; Busschbach JJ
    Value Health; 2010; 13(2):289-97. PubMed ID: 19744296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inconsistencies in TTO and VAS values for EQ-5D health states.
    Lamers LM; Stalmeier PF; Krabbe PF; Busschbach JJ
    Med Decis Making; 2006; 26(2):173-81. PubMed ID: 16525171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosswalk EQ-5D-5L Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M
    Zdr Varst; 2020 Sep; 59(3):189-194. PubMed ID: 32952720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
    Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
    Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies.
    Zrubka Z; Golicki D; Prevolnik-Rupel V; Baji P; Rencz F; Brodszky V; Gulácsi L; Péntek M
    Eur J Health Econ; 2019 Jun; 20(Suppl 1):141-154. PubMed ID: 31102159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methods.
    Craig BM; Busschbach JJ; Salomon JA
    Med Care; 2009 Jun; 47(6):634-41. PubMed ID: 19433996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An experience- and preference-based EQ-5D-3L value set derived using 18 months of longitudinal data in patients who sustained a fracture: results from the ICUROS.
    Svedbom A; Borgstöm F; Hernlund E; Alekna V; Bianchi ML; Clark P; Diaz-Curiel M; Dimai HP; Jürisson M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA
    Qual Life Res; 2023 Apr; 32(4):1199-1208. PubMed ID: 36495384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
    Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
    Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argentine valuation of the EQ-5D health states.
    Augustovski FA; Irazola VE; Velazquez AP; Gibbons L; Craig BM
    Value Health; 2009 Jun; 12(4):587-96. PubMed ID: 19900257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.